Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$37.91M
Enterprise ValueAU$14.04M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$9.70M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity of 0.12 indicates manageable leverage and a healthy equity base. Lower financial leverage reduces bankruptcy risk and preserves capacity to fund clinical programs or absorb shocks without immediate external financing, supporting medium-term resilience.
Service + Research Revenue MixA dual model of fee-for-service clinical operations plus contracted research/clinical trials diversifies income streams. Service revenues can provide recurring cash receipts while research contracts can fund validation and partnerships, aiding longer-term commercialization pathways.
Lean Operating StructureA very small employee base implies a low fixed cost footprint and operational agility. This lean structure can extend cash runway and allow targeted investment in trials or clinical services without large overhead, useful while scaling or seeking financing.
Bears Say
Declining Revenue & Negative MarginsA 21% revenue decline combined with negative gross, EBIT/EBITDA and net margins shows the core business is shrinking and unprofitable. Persisting top-line contraction and margin losses will erode capital, limit reinvestment and hamper ability to validate or commercialize treatments.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow creates reliance on external financing to maintain operations and fund trials. Even with high FCF growth rates, current cash deficits reduce flexibility, increase dilution risk and constrain long-term R&D and service expansion plans.
Negative Return On EquityA negative ROE indicates the company is not generating returns on shareholder capital, reflecting inefficient use of equity and weak profitability. Over time, this undermines investor confidence and makes raising growth capital or forming large partnerships more difficult.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.03 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$37.91M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 40 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,561,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EMD Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
170.82%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
―